Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1096]

Talazoparib plus enzalutamide improves radiographic progression-free survival...

Dr Neeraj Agarwal - University of Utah, Salt Lake City, USA

Talazoparib plus enzalutamide improves radiographic progression-free survival in HRR-altered mCSPC ( Dr Neeraj Agarwal - University of Utah, Salt Lake City, USA )

ASCO 2026: Highlights and analysis

Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada

ASCO 2026: Highlights and analysis ( Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada )

ASCO 2026: Latest in prostate cancer

Prof Eleni Efstathiou, Prof Boris Hadaschik, Dr Mary-Ellen Taplin and Prof Axel...

ASCO 2026: Latest in prostate cancer ( Prof Eleni Efstathiou, Prof Boris Hadaschik, Dr Mary-Ellen Taplin and Prof Axel Merseburger )

177Lu-rosopatamab plus standard of care shows manageable safety and favourable...

Dr Pedro Barata - University Hospitals Seidman Cancer Center, Cleveland, USA

177Lu-rosopatamab plus standard of care shows manageable safety and favourable tumour targeting in mCRPC ( Dr Pedro Barata - University Hospitals Seidman Cancer Center, Cleveland, USA )

Xaluritamig plus abiraterone shows promising anti-tumour activity with...

Dr David Pook - Monash Health, Melbourne, Australia

Xaluritamig plus abiraterone shows promising anti-tumour activity with manageable safety in chemotherapy-naïve mCRPC ( Dr David Pook - Monash Health, Melbourne, Australia )

miR371 shows promise as a surveillance biomarker for relapse in early-stage...

Dr Lucia Nappi - University of British Columbia, Vancouver, Canada

miR371 shows promise as a surveillance biomarker for relapse in early-stage germ cell tumours ( Dr Lucia Nappi - University of British Columbia, Vancouver, Canada )

Yoga improves mood, fatigue, and insomnia in cancer survivors following...

Dr Karen Mustian - Wilmot Cancer Institute, Rochester, USA

Yoga improves mood, fatigue, and insomnia in cancer survivors following treatment ( Dr Karen Mustian - Wilmot Cancer Institute, Rochester, USA )

Apalutamide plus ADT improves surgical outcomes in high-risk prostate cancer

Dr Adam Kibel - Dana-Farber Cancer Institute, Boston, USA

Apalutamide plus ADT improves surgical outcomes in high-risk prostate cancer ( Dr Adam Kibel - Dana-Farber Cancer Institute, Boston, USA )

ASCO 2026: Latest updates in mRCC

Dr Toni Choueiri, Prof Viktor Grünwald, Dr Martin Voss and Prof Jens Bedke

ASCO 2026: Latest updates in mRCC ( Dr Toni Choueiri, Prof Viktor Grünwald, Dr Martin Voss and Prof Jens Bedke )

Darolutamide shows less cognitive decline than enzalutamide in advanced...

Dr Alicia Morgans - Dana-Farber Cancer Institute, Boston, USA

Darolutamide shows less cognitive decline than enzalutamide in advanced prostate cancer ( Dr Alicia Morgans - Dana-Farber Cancer Institute, Boston, USA )

Combination therapeutic strategies for aRCC patients with bone metastases

Prof Stéphane Oudard and Dr Stefanie Zschäbitz

Combination therapeutic strategies for aRCC patients with bone metastases ( Prof Stéphane Oudard and Dr Stefanie Zschäbitz )

Part 1: Why test?

Dr Elena Castro - Hospital Universitario 12 de Octubre, Madrid, Spain

Part 1: Why test? ( Dr Elena Castro - Hospital Universitario 12 de Octubre, Madrid, Spain )

More from ecancer